TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00927368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance alone
Description: The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance and needle stimulation
Description: For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance and catheter stimulation
Description: The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
Study: NCT02624492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GemOx

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GemOx
Study: NCT03909360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drainage tube
Description: sub-hepatic drainage tube for laparoscopic cholecystectomy
Study: NCT01019018

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subtenon block
Description: subtenon block with stevens cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subtenon block
Description: subtenon block with Olive tip cannula cannula
Study: NCT00858429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
Study: NCT00783393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
Study: NCT04428411

Intervention type: DRUG
Intervention: Enbrel
Description: As provided in real world practice
Study: NCT01163786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
Study: NCT02805205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study: NCT03942315

Intervention type: OTHER
Intervention: Data collection from standard follow-up after liver transplant
Description: All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.
Study: NCT04137783

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study, only observation.

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study, only observation.

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study, only observation.
Study: NCT04444856

Intervention type: OTHER
Intervention: Standard of care
Description: The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
Study: NCT01654900

Intervention type: OTHER
Intervention: No intervention in this study
Study: NCT00132730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 1.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 0.75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-0873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-0873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-0873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-0873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT00781157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine bolus
Description: The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose.
Study: NCT01642641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical Subgingival Debridement (SD)
Description: SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
Study: NCT03471078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Oral avatrombopag tablet
Study: NCT01642641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simplified Papilla Preservation Flap
Description: The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resective Periodontal Flap with Osseous Recontouring (RPFO)
Description: RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
Study: NCT01554579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Placebo
Study: NCT02303717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary stent implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Description: Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy
Description: Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
Study: NCT03850184

Intervention type: DIAGNOSTIC_TEST
Intervention: The Exercise in Mental Illness Questionnaire (EMIQ)
Description: Questionnaire assessing prescription behaviour, knowledge, barriers and behaviour of physical activity in mental health professionals
Study: NCT03175341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: 100 ml normal saline 0.9%
Study: NCT03979326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Static stretching lasting 3 x 45 seconds will be performed in each of the examined women three times in different phases of the menstrual cycle: follicular, ovulatory and luteal. Before and after the intervention, a series of tests assessing the influence of stretching on biomechanical parameters will be carried out
Study: NCT02266030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Pletaal as an active drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin as an active comparator
Study: NCT01808612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study: NCT03234569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sonoHSG
Description: This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image. For the ultrasound images, General Electric will be supporting us by providing us the Voluson E10 and RIC5-9-D.
Study: NCT03471078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator tablet
Study: NCT01881048

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO
Study: NCT01808612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03621579

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
Study: NCT01276730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon, Retinoic Acid and radiation
Description: Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
Study: NCT02816879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo anal cytology collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04628546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Parenting Young Children Check-up Initial Check-up and Text Messages
Description: Parents assigned to the intervention condition will go through the Initial Check-up, which is a brief intervention that uses motivational content to promote use of the Parenting Young Children Check-up parenting education website. They will also receive text messages and a brochure to connect them to the parenting education website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Parenting Young Children Check-up Flier and Text Messages
Description: Parents assigned to the control condition will not go through the Parenting Young Children Check-up Initial Check-up. They will only go through assessment and then see a brief flier about the Parenting Young Children. Like the intervention condition, they will also receive text messages and a brochure to connect them to the Parenting Young Children Check-up parenting education website.
Study: NCT01827631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 capsule
Description: Swedish Orange, size 0, hard gelatine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 capsule
Description: Swedish Orange, size 0, hard gelatine capsules
Study: NCT01835119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gum
Description: gum
Study: NCT01648257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Na Salt Tablets
Description: Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Free Acid Nanomilled Capsules
Description: Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Free Acid Micronized Capsules
Description: Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
Study: NCT04457960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-66525433
Description: Participants will receive JNJ-66525433 oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo oral capsules.
Study: NCT04401033

Intervention type: BEHAVIORAL
Intervention: Telephonic medical visit
Description: The patient will receive a telephonic call passing a medical visit

Intervention type: PROCEDURE
Intervention: Gastrointestinal endoscopy
Description: Upper or lower GI endoscopy according to clinical practice and current guidelines

Intervention type: PROCEDURE
Intervention: Abdominal ultrasound
Description: Diagnostic abdominal ultrasound according to the current guidelines
Study: NCT02953145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisseel
Description: Tisseel will be applied to open areas lateral to the cleft palate repair
Study: NCT01351441

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medication adherence consultation
Description: Patients will be counseled in person on day 0 then telephonically every month after until day 365.

Intervention type: OTHER
Group type: OTHER
Intervention: Medication problems assessment
Description: Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
Study: NCT01276730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin and radiation
Description: Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
Study: NCT04455581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
Study: NCT02903888

Intervention type: DRUG
Intervention: Levonorgestrel (Jaydess, Skyla, BAY86-5028)
Description: Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
Study: NCT01351441

Intervention type: OTHER
Group type: OTHER
Intervention: Beer's Criteria Assessment
Description: The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Literacy Assessment
Description: Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
Study: NCT04451330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene cream
Description: Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Description: Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trifarotene Vehicle
Description: Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline Placebo
Description: Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
Study: NCT04905667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB221
Description: 6 mg/kg, single dose, intravenous infusion, 90-100 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: 6 mg/kg, single dose, intravenous infusion, 90-100 min
Study: NCT01307930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
Study: NCT03075163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
Study: NCT02065453

Intervention type: DEVICE
Group type: OTHER
Intervention: disposable device (Ligasure, Covidien)
Description: One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon.

Intervention type: DEVICE
Group type: OTHER
Intervention: disposable device (Ligasure, Covidien)
Description: One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon.

Intervention type: DEVICE
Group type: OTHER
Intervention: Reusable device
Description: One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic

Intervention type: DEVICE
Group type: OTHER
Intervention: Reusable device
Description: One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
Study: NCT00844233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irinotecan Bead
Description: Irinotecan eluting bead
Study: NCT05014477

Intervention type: PROCEDURE
Intervention: Removal or leaving of LAA occluders
Description: After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
Study: NCT03120832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PAN-301-1
Study: NCT00556426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard Recovery G2 Filter System
Description: Retrieval of previously placed RECOVERY G2 IVC filter